###begin article-title 0
###xml 75 97 75 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 75 96 <span type="species:ncbi:5833">Plasmodium falciparum</span>
The malaria candidate vaccine liver stage antigen-3 is highly conserved in Plasmodium falciparum isolates from diverse geographical areas
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 169 190 169 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 211 217 211 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 169 190 <span type="species:ncbi:5833">Plasmodium falciparum</span>
A high level of genetic stability has been formerly identified in segments of the gene coding for the liver stage antigen-3 (LSA-3), a subunit vaccine candidate against Plasmodium falciparum. The exploration of lsa-3 polymorphisms was extended to the whole sequence of this large antigen in 20 clinical isolates from four geographical areas; Senegal, Comoro islands, Brazil and Thailand.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 190 204 190 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 190 203 <span type="species:ncbi:5833">P. falciparum</span>
The whole 4680 bp genomic sequence of lsa-3 was amplified by polymerase chain reaction and sequenced. The clinical isolate sequences were aligned on the sequence of the laboratory reference P. falciparum strain 3D7.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
The non-repeated sequence of lsa-3 was very well conserved with only a few allelic variations scattered along the sequence. Interestingly, a formerly identified immunodominant region, employed for the majority of pre-clinical vaccine development, was totally conserved at the genetic level. The most significant variations observed were in the number and organization of tetrapeptide repeated units, but not in their composition, resulting in different lengths of these repeated regions. The shorter repeated regions were from Brazilian origin. A correlation between the geographical distribution of the parasites with single nucleotide polymorphisms was not detected.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
The lack of correlation between allelic polymorphisms with a specific transmission pressure suggests that LSA-3 is a structurally constrained molecule. The unusual characteristics of the lsa-3 gene make the molecule an interesting candidate for a subunit vaccine against malaria.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 27 49 27 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 170 171 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 255 256 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 762 776 762 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 866 867 866 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 27 48 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 160 168 <span type="species:ncbi:9606">children</span>
###xml 762 775 <span type="species:ncbi:5833">P. falciparum</span>
The human malaria parasite Plasmodium falciparum is responsible for 300-500 million clinical cases and 1-2 million deaths every year mainly among young African children [1]. The incidence of malaria among travellers from non-endemic areas is on the rise [2]. The emergence and spread of resistances against anti-malarial drugs makes the development of a vaccine an urgent need. Naive volunteers immunized with radiation-attenuated sporozoites [3], the form of the parasite injected in the host by a mosquito bite, but not killed parasites, were protected from a challenge with wild-type parasites. This observation suggests that the partial intra-hepatic development of the parasite was necessary to confer protection against the pre-erythrocytic (PE) stages of P. falciparum as it has been further verified with recently developed genetically attenuated parasites [4].
###end p 11
###begin p 12
###xml 122 136 122 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 634 647 634 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 763 764 763 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 765 766 765 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 899 900 899 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 997 998 997 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1250 1251 1250 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1379 1380 1379 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1381 1383 1381 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1384 1386 1384 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1497 1499 1497 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1796 1798 1796 1798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1859 1873 1859 1873 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 1977 1979 1977 1979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 122 135 <span type="species:ncbi:5833">P. falciparum</span>
###xml 634 647 <span type="species:ncbi:5833">P. falciparum</span>
###xml 922 927 <span type="species:ncbi:9606">human</span>
###xml 1338 1344 <span type="species:ncbi:10090">murine</span>
###xml 1594 1600 <span type="species:ncbi:10090">murine</span>
###xml 1859 1872 <span type="species:ncbi:5833">P. falciparum</span>
###xml 1967 1975 <span type="species:ncbi:9606">patients</span>
A subset of twenty parasite antigens expressed during the PE stages were identified by screening an expression library of P. falciparum with sera from Europeans living in endemic areas that followed a continuous prophylactic treatment against the pathogenic blood stages of the parasite [5]. The liver stage antigen-3 (LSA-3) was further selected using discriminating sera of volunteers immunized by radiation-attenuated parasites that were protected against an experimental challenge versus sera from volunteers receiving over-irradiated parasites who were not protected. LSA-3 is a molecule of 1558 amino acids in the strain 3D7 of P. falciparum, which includes a majority of non-repetitive sequences and a block of tetrapeptide repeats organized in a-helices [6,7]. These repeats contain the motif E-E-X-hydrophobic amino acid-E-E shared by three other parasite antigens; RESA, Pf11.1 and Ag332 [8] and recognized by a human monoclonal antibody developed against a parasite of Liberian origin [9]. LSA-3 is the only molecule of this cross-reacting family of glutamic acid dipeptides-containing antigens that is specifically expressed during the PE stages, both on the surface of sporozoites and in the parasitophorous membrane in the liver cells [7]. The immunogenicity and protective potential of LSA-3 was established by a series of murine and primate pre-clinical studies [7,10-12]. Its antigenicity was demonstrated by several immuno-epidemiological studies in malaria-exposed populations [13]. The implication of LSA-3 in the immune response against the PE stages was demonstrated in a murine model where intra-hepatic granulomas of immune cells developed both around the liver forms and around LSA-3 peptide-coated beads that were injected in the portal vein of LSA-3 immunized animals [14]. Recently, an early serodiagnosis test at the PE stages of P. falciparum infection was developed with a recombinant LSA-3 enzyme-linked immunosorbent assay in Burmese patients [15], and in French troops stationed in Africa (Pradines, Rogier, personal communication).
###end p 12
###begin p 13
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 497 499 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
The antigens polymorphism represents a major hurdle in the development of vaccines against malaria [16]. Natural epitope polymorphisms require to include all known alleles in a given vaccine formulation and, in addition can alter the nature of the immune response against the original epitope. Indeed, CSP-specific CD4+ T cells shifted their cytokine production from IFN-gamma towards the immunosuppressive interleukin-10 in presence of the variant epitope called an altered peptide ligand (APL) [17].
###end p 13
###begin p 14
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 299 302 299 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa</italic>
###xml 625 631 625 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
Owing to the vaccine potential of LSA-3, the genetic stability of this antigen in clinical isolates from different areas of the world was investigated. The former results obtained on an immunodominant region of LSA-3 were confirmed in this study [7,10] and extended to the whole genetic sequence of lsa-3. Strikingly, this molecule appears to be strongly conserved in samples from such distant areas as South America, Africa and South East Asia. The only significant variations consisted in the number of tetrapeptides repeated units, but not in their composition. No obvious geographical pattern of allelic diversity in the lsa-3 gene was identified. This characteristic adds arguments in favour of the usefulness of this molecule in a subunit vaccine against malaria.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 22 44 22 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 22 43 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Genomic material from Plasmodium falciparum strains
###end title 16
###begin p 17
Genomic DNA from field isolates of the parasite blood stages was obtained by extraction with the Qiamp DNA blood minikit (Qiagen, USA) on blood samples received from Dielmo in Senegal (n = 7), Brazil (n = 5), Comoro islands (n = 6) and Thailand (n = 2). Nucleotide sequence data reported in this paper are available in the GenBanktrade mark, EMBL and DDBL databases under the accession numbers GQ222688-GQ22707.
###end p 17
###begin title 18
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3</italic>
PCR amplification, cloning and sequencing of lsa-3
###end title 18
###begin p 19
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 87 88 87 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 159 165 159 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 200 214 200 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 312 318 312 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 588 589 587 588 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1194 1211 1162 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 200 213 <span type="species:ncbi:5833">P. falciparum</span>
###xml 1194 1210 <span type="species:ncbi:562">Escherichia coli</span>
The complete sequence of lsa-3 was obtained by a set of six PCR amplifications (Figure 1) with the corresponding PCR primer pairs (Table 1) designed after the lsa-3 sequence found in the strain K1 of P. falciparum (GenBank accession number: ) [7]. The sequences of the PCR primers originally designed to amplify lsa-3 from the strain K1 matched the sequence in the strain 3D7 (GenBank accession number: ) [18]. The PCR reactions were performed on genomic DNA with 2,5 units of AmpliTaq DNA polymerase (Roche, USA) in a final volume of 50 muL of a buffer solution containing 1,5 mM of MgCL2, 800 muM of dNTPs and 500 nM of primers. The cycling programme was; 94degreesC/2 min, [(94degreesC/15 sec, 57degreesC/30 sec, 72degreesC/1 min) x 35], 72degreesC/2 min, on a PTC-200 thermal cycler (MJ Research). Two sets of PCR amplifications were serially completed on the same samples to prevent ambiguities introduced by the Taq polymerase and thereby confirm any observed mutation. The PCR fragments were purified by electrophoresis in an agarose gel and extracted with the Qiaquick gel extraction kit (Qiagen) before to be introduced in the sequencing plasmid vector pCR4-TOPO. Chemically competent Escherichia coli Top 10 bacteria were transformed with an aliquot of the reaction according to the manufacturer instructions (Invitrogen, USA). Plasmids from recombinant bacteria were prepared with the QIAprep miniprep kit (Qiagen, USA) and analysed by restriction enzymatic digestion. The fragment-containing plasmids were sent to a genomics company for sequencing (Cogenics, Meylan, France).
###end p 19
###begin p 20
###xml 35 55 35 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum lsa-3 </italic>
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Diagrammatic representation of the <italic>P. falciparum lsa-3 </italic>gene</bold>
###xml 35 48 <span type="species:ncbi:5833">P. falciparum</span>
Diagrammatic representation of the P. falciparum lsa-3 gene. The intron is shown as a single line. Sequences coding for the repeated regions I, II and III of the LSA-3 protein are depicted as hatched boxes in exon 2. Fragments amplified by PCR for sequencing are shown below.
###end p 20
###begin p 21
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
Primer pairs used to amplify the lsa-3 gene in clinical isolates genomic material.
###end p 21
###begin p 22
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 83 97 83 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 83 96 <span type="species:ncbi:5833">P. falciparum</span>
a, PCR fragment length in base pairs according to the lsa-3 nucleotide sequence in P. falciparum strain 3D7.
###end p 22
###begin title 23
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
Analysis of lsa-3 sequences
###end title 23
###begin p 24
###xml 473 479 473 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 495 509 495 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 572 574 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 669 670 669 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 729 730 729 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 936 942 936 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 972 986 972 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 495 508 <span type="species:ncbi:5833">P. falciparum</span>
###xml 972 985 <span type="species:ncbi:5833">P. falciparum</span>
The mutations observed after the two sets of PCR amplifications were considered as true polymorphisms whereas mutations observed after a single set of PCR were considered as errors introduced by the Taq polymerase in the amplification step. The sequencing traces were aligned with the SeqMan software (Lasergene, Germany). The derived nucleic and protein sequences were aligned by the MegAlign software (Lasergene, Germany) using the clustalW algorithm and compared to the lsa-3 sequence of the P. falciparum laboratory strain 3D7 believed to have originated from Africa [18]. Sequences coding for repeats in the molecule were further aligned manually (Additional file 1). The sequences corresponding to the short intron (Figure 1) were ignored because of the difficulty to reliably amplify this region composed by long strings of A and T nucleotides. Numerations of nucleic and protein sequences were done according to the sequence of lsa-3 mRNA and LSA-3 protein of the P. falciparum strain 3D7.
###end p 24
###begin title 25
Results and discussion
###end title 25
###begin title 26
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
Amplification of the lsa-3 gene
###end title 26
###begin p 27
###xml 131 137 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 164 178 164 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 179 180 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 215 221 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 164 177 <span type="species:ncbi:5833">P. falciparum</span>
The amplification of the gene was achieved by using PCR primers based on the sequence of the previously cloned and fully sequenced lsa-3 gene from the strain K1 of P. falciparum [7]. A scheme of the DNA sequence of lsa-3 in the generic strain 3D7 is shown in the Figure 1 with the location and size of the six fragments amplified. The primer pairs (Table 1) were fully operative on the 20 clinical isolates analysed, even with a stringent annealing temperature of 57degreesC in the PCR programme.
###end p 27
###begin title 28
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
Polymorphism of lsa-3 at the genetic and protein levels in the non-repeated regions
###end title 28
###begin p 29
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 389 390 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 411 412 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 580 586 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 708 709 708 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 829 834 829 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3</italic>
###xml 834 841 834 841 <sub xmlns:xlink="http://www.w3.org/1999/xlink">410-775</sub>
###xml 919 921 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1023 1037 1023 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 1077 1079 1077 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 1164 1166 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1271 1273 1271 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1023 1036 <span type="species:ncbi:5833">P. falciparum</span>
The sequences of the full length of the lsa-3 gene from the 20 clinical isolates were compared with the published sequence of the laboratory strain 3D7 [18]. The number of punctual mutations in the sequence coding for the large non-repeated regions of the molecule among the 20 isolates was remarkably low with only 15 single nucleotide polymorphisms (SNPs) out of 3444 base pairs (Figure 2 and Additional file 2). Five of these were synonymous mutations (33%) whereas 10 were non-synonymous resulting in amino acid changes. This was not unexpected because the full sequencing of lsa-3 in the laboratory strain K1 of Thai origin reported six SNPs along the same sequence with two synonymous mutations (33%) [7]. Moreover, the complete conservation at the genetic level of a sequence coding for an immunodominant region of LSA-3 (lsa-3410-775) that was previously observed in 27 samples from diverse geographical areas [10] was confirmed in the samples analysed in this study. These frequencies are much lower than in other P. falciparum vaccine candidates, such as for example PfAMA1 with 130 non-synonymous mutations out of 1,800 base pairs in 13 Indian samples [19]. The silent mutation a3882c identified on 12 out of 18 Gambian isolates in a sequence coding for la90 [20], a peptide recognized by the molecule of the histocompatiblity complex HLA-B53 that is associated with resistance to severe malaria in West Africa was not observed in this study.
###end p 29
###begin p 30
###xml 47 61 47 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 0 78 0 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Nucleotide and protein sequences of LSA-3 from <italic>P. falciparum </italic>clinical isolates</bold>
###xml 331 338 331 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink">667-834</sub>
###xml 350 358 350 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink">835-1758</sub>
###xml 374 383 374 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3910-4047</sub>
###xml 47 60 <span type="species:ncbi:5833">P. falciparum</span>
Nucleotide and protein sequences of LSA-3 from P. falciparum clinical isolates. The nucleotide sequence of the codons from the reference strain 3D7 with the positions of mutated bases in bold are shown on top. The mutated codons for each clinical isolates are shown below. Sequences corresponding to the repeated sequences I (LSA-3667-834), II (LSA-3835-1758) and III (LSA-33910-4047) are omitted and represented by three dots. The corresponding amino acid changes resulting from non-synonymous mutations are shown below amino acid residues found in the reference strain 3D7. Identical codons and amino acid residues are represented by hyphens. del denotes a deletion of a codon and the corresponding amino acid.
###end p 30
###begin p 31
###xml 73 74 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 670 675 670 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3</italic>
###xml 675 684 675 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4121-4122</sub>
The singleton variations could be classified in three categories (Figure 2). Firstly, singletons observed in a single isolate as a157g in Com 119, t247c in Sen 5522, a1778g in Sen 5514, g2629a in Sen 5505, and c3556t in Sen 5510. Secondly, singletons or group of singletons that were associated with a group of isolates; a1957g, c1998t and g3108a in Bra 1905 and Bra 1884, g2136a in Sen 5510, Sen 5514, Tha 28, Tha 52 and the laboratory strain K1, c4340t in Brazilian isolates 1915, 1882 and 1853. Thirdly, singletons seen in most of the isolates compared to the generic sequence of the strain 3D7, a237t, g2144a, g3108a, a3786g and t4656a. A deletion of the codon gaa (lsa-34121-4122) was detected in isolates Bra 1905, Bra 1884 and Sen 5522.
###end p 31
###begin p 32
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
The very low number of SNPs in lsa-3 compared to most of the actual malaria candidate vaccines, mainly expressed during the asexual blood stages (ABS), might relate to the PE expression of the protein. The PE antigens are likely less exposed to immunological pressure; Firstly, because of the tremendously lower numbers of PE schizonts as compared to ABS schizonts [21]. Secondly, once injected in the host blood by an infected mosquito, the sporozoites infect liver cells within a few minutes were they expand and mature inside hepatocytes hidden from antibodies. Finally, the liver maintains a tolerogenic response towards incoming harmless antigens [22] that might favour the development of the parasite.
###end p 32
###begin p 33
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">msp-3 </italic>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
However, the sequence of msp-3 coding for the C-terminal region of the merozoite surface protein-3, which is expressed on the surface of merozoites in ABS that are more exposed to immune surveillance, was also remarkably conserved in the same clinical isolates [23]. These results suggest that, independently of the stage of expression, mechanisms such as structural constraints may drive the genetic stability observed in these antigens and act against the occurrence of mutations.
###end p 33
###begin title 34
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3</italic>
Polymorphism of the repeated regions of lsa-3
###end title 34
###begin p 35
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
The amplification of the sequence coding for the repeated contiguous regions I and II of LSA-3 showed considerable size variation ranging from 264 nucleotides in the isolate Bra 1853 to 1800 in the K1 strain, respectively (Figure 3). The figure 4 illustrates the corresponding number of tetrapeptide repeats ranging from 22 in the sample Bra 1853 to 150 in the laboratory strain K1.
###end p 35
###begin p 36
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 0 109 0 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>lsa-3 </italic>repeats-coding fragments amplified by PCR showing the size polymorphism of the repeated region I and II</bold>
lsa-3 repeats-coding fragments amplified by PCR showing the size polymorphism of the repeated region I and II.
###end p 36
###begin p 37
###xml 0 137 0 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Number of tetrapeptide repeated units in the LSA-3 regions I and II of the 20 clinical isolates and the two laboratory strains 3D7 and K1</bold>
Number of tetrapeptide repeated units in the LSA-3 regions I and II of the 20 clinical isolates and the two laboratory strains 3D7 and K1.
###end p 37
###begin p 38
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
The region I is composed of 14 tetrapeptides in the strain 3D7. Deletions of six tetrapeptides in isolates Bra 1915, Bra 1882 and Bra 1853 and insertions of two tetrapeptides in Com 524 were detected (Additional file 1). The polymorphism E253G was observed in all strains but not in the strain 3D7. This suggests that the glutamic acid residue at the position 253 of the LSA-3 protein in the strain 3D7 could result from an artificially introduced mutation during the sequencing process of the gene.
###end p 38
###begin p 39
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
The region II contributes the most to the repeat length heterogeneity between isolates (Figures 3 and 4, Additional file 1). Unique tetrapeptides were identified in isolates Sen 5522 (DDGS, VASS, IASS, VDES, IDSS), Sen 5514 (VVEN), Com 119 (VAED, VAEK) and Com 524 (VVPS).
###end p 39
###begin p 40
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
The region III show little variations compared to the sequence of 3D7 composed of eleven tetrapeptides with only a tetrapeptide deletion in all strains but Tha 28 (no deletion) and Com 119 (two deletions) (Additional file 1). The repeats composition were identical in all strains apart from two polymorphisms in Sen 5533 changing a tetrapeptide IDED to a unique IEEN.
###end p 40
###begin p 41
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
The results show that apart from some unique repeats in region II, the composition of most of the tetrapeptide repeats was identical in all strains but solely their number and organisation in the repeated regions varied (Figures 3 and 4, Additional file 1).
###end p 41
###begin p 42
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 68 69 68 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 162 168 162 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lsa-3 </italic>
###xml 564 565 564 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
Overall, twenty-two SNPs scattered along the lsa-3 sequence (Figure 2 and Additional files 1 and 2) were identified. The polymorphisms in the repeated regions of lsa-3 consisted mainly in insertions, deletions and/or reorganizations of sequences coding for the same tetrapeptide units in LSA-3. Although the number of clinical isolates analysed did not allow to draw definitive conclusions, the samples from Brazil seemed to contain the shorter repeated regions whereas samples originating from Thailand with the laboratory strain K1 contained the largest (Figure 4). At a time when the polymorphism of LSA-3 had not yet been investigated, it is this particular criterion, of longer length, that led us to choose K1 for molecular characterization of the gene. Hence, the particular length of LSA-3 in K1 is not a surprise, and results now indicate that this size is only due to repeats duplications.
###end p 42
###begin p 43
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 848 850 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
The strong disparity in the number of repeats in region I and II suggest that the length of this area of the molecule is dispensable for the fitness of the parasite. The repetitive organization of these sequences usually produces B cell epitopes that are immunodominant in other genes, as compared to non-repeated regions. It has been proposed that repeated sequences might act on the intensity and quality of the immune response [24] and thus contribute to the immune escape of the parasite. A putative escape mechanism could be to divert the immune response from protective epitopes towards these repeated regions of the parasite antigens. However, in the case of LSA-3, detailed immunological studies in hyperendemic areas revealed that B-cell epitopes defined in non-repeated regions were as much the target of antibodies as the repeat blocks [13]. Hence, in contrast to other genes encoding repeats and particularly Glu-rich repeats, the Glu-rich block of LSA-3 does not seem to be immunodominant. The presence of such repeats in several malarial antigens and the network of cross-reactivity they generate across those molecules have been frequently stressed, however their functions remain poorly understood.
###end p 43
###begin title 44
Conclusion
###end title 44
###begin p 45
###xml 63 77 63 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum </italic>
###xml 63 76 <span type="species:ncbi:5833">P. falciparum</span>
LSA-3 is a highly conserved antigen among clinical isolates of P. falciparum originating from diverse geographical areas. There is a significant allelic polymorphism solely in the number and organization of the repeated tetrapeptide units. These results question the functionality of the repeated regions of LSA-3 and other genes containing similar structures, and their interaction with the immune system. The paucity of single nucleotide polymorphisms is a positive feature for the development of LSA-3 as a deployable subunit vaccine candidate against malaria for populations living in endemic areas as well as for naive travellers. However, the effect of LSA-3 repeats length on the host immune response should be carefully analysed and the vaccine candidate tailored accordingly.
###end p 45
###begin title 46
Competing interests
###end title 46
###begin p 47
The authors declare that they have no competing interests.
###end p 47
###begin title 48
Authors' contributions
###end title 48
###begin p 49
EP carried out the molecular genetic studies, the sequence alignment and drafted the manuscript. PD participated in the design of the study. Both authors read and approved the final manuscript.
###end p 49
###begin title 50
Supplementary Material
###end title 50
###begin title 51
Additional file 1
###end title 51
###begin p 52
###xml 80 102 80 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 0 116 0 116 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Alignments of amino acid sequences corresponding to the repeated regions of the <italic>Plasmodium falciparum </italic>LSA-3 molecule</bold>
###xml 80 101 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Alignments of amino acid sequences corresponding to the repeated regions of the Plasmodium falciparum LSA-3 molecule. The sequences of LSA-3 from 20 clinical isolates from Senegal, Comoro islands, Brazil, Thailand and the laboratory strain K1 are compared to the one of the generic strain 3D7 (Plasmo dB accession number: PFB0915w).
###end p 52
###begin p 53
Click here for file
###end p 53
###begin title 54
Additional file 2
###end title 54
###begin p 55
###xml 84 106 84 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 0 120 0 120 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Alignments of amino acid sequences corresponding to the non-repeated regions of the <italic>Plasmodium falciparum </italic>LSA-3 molecule</bold>
###xml 84 105 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Alignments of amino acid sequences corresponding to the non-repeated regions of the Plasmodium falciparum LSA-3 molecule. The sequences of LSA-3 from 20 clinical isolates from Senegal, Comoro islands, Brazil, Thailand and the laboratory strain K1 are compared to the one of the generic strain 3D7 (Plasmo dB accession number: PFB0915w).
###end p 55
###begin p 56
Click here for file
###end p 56
###begin title 57
Acknowledgements
###end title 57
###begin p 58
This study was financially supported by a European Community grant number QLK2-CT-2001-01886.
###end p 58
###begin article-title 59
###xml 28 50 28 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 28 49 <span type="species:ncbi:5833">Plasmodium falciparum</span>
The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide
###end article-title 59
###begin article-title 60
Imported malaria in a cosmopolitan European city: a mirror image of the world epidemiological situation
###end article-title 60
###begin article-title 61
###xml 79 101 79 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 14 20 <span type="species:ncbi:9606">humans</span>
###xml 79 100 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites
###end article-title 61
###begin article-title 62
###xml 33 55 33 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 33 54 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design
###end article-title 62
###begin article-title 63
###xml 14 36 14 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 14 35 <span type="species:ncbi:5833">Plasmodium falciparum</span>
How to select Plasmodium falciparum pre-erythrocytic antigens in an expression library without defined probe
###end article-title 63
###begin article-title 64
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 0 21 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Plasmodium falciparum: D260, an intraerythrocytic parasite protein, is a member of the glutamic acid dipeptide-repeat family of proteins
###end article-title 64
###begin article-title 65
###xml 19 41 19 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 19 40 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 52 63 <span type="species:ncbi:9598">chimpanzees</span>
Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3
###end article-title 65
###begin article-title 66
###xml 59 81 59 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 59 80 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Cross-reactive antigenic determinants present on different Plasmodium falciparum blood-stage antigens
###end article-title 66
###begin article-title 67
###xml 26 47 26 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 26 47 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 94 99 <span type="species:ncbi:9606">human</span>
Cytoadherence of knobless Plasmodium falciparum-infected erythrocytes and its inhibition by a human monoclonal antibody
###end article-title 67
###begin article-title 68
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 174 185 <span type="species:ncbi:9598">chimpanzees</span>
Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees
###end article-title 68
###begin article-title 69
###xml 41 63 41 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 41 62 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 86 91 <span type="species:ncbi:9606">human</span>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice
###end article-title 69
###begin article-title 70
###xml 42 64 42 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 84 113 84 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aotus lemurinus griseimembra </italic>
###xml 42 63 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 84 112 <span type="species:ncbi:292213">Aotus lemurinus griseimembra</span>
Immunogenicity and protective efficacy of Plasmodium falciparum liver-stage Ag-3 in Aotus lemurinus griseimembra monkeys
###end article-title 70
###begin article-title 71
###xml 48 69 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3
###end article-title 71
###begin article-title 72
###xml 83 105 83 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 83 104 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Analysis of intra-hepatic peptide-specific cell recruitment in mice immunised with Plasmodium falciparum antigens
###end article-title 72
###begin article-title 73
###xml 82 104 82 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 82 103 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Usefulness of the recombinant liver stage antigen-3 for an early serodiagnosis of Plasmodium falciparum infection
###end article-title 73
###begin article-title 74
###xml 24 46 24 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum </italic>
###xml 24 45 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Genetic polymorphism in Plasmodium falciparum vaccine candidate antigens
###end article-title 74
###begin article-title 75
###xml 77 98 77 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 77 98 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum
###end article-title 75
###begin article-title 76
###xml 46 67 46 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 46 67 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Genome sequence of the human malaria parasite Plasmodium falciparum
###end article-title 76
###begin article-title 77
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium falciparum</italic>
###xml 0 21 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Plasmodium falciparum: genetic polymorphism in apical membrane antigen-1 gene from Indian isolates
###end article-title 77
###begin article-title 78
Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3
###end article-title 78
###begin article-title 79
Malaria parasite pre-erythrocytic stage infection: gliding and hiding
###end article-title 79
###begin article-title 80
Local control of the immune response in the liver
###end article-title 80
###begin article-title 81
Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3
###end article-title 81
###begin article-title 82
Molecular basis for evasion of host immunity and pathogenesis in malaria
###end article-title 82

